Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT03703167
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 14
- Registration Number
- NCT03702725
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The Ohio State University Wexner Medical Center/James Cancer Hospital, Columbus, Ohio, United States
Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 11
- Registration Number
- NCT03701711
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸The Ohio State University Medical Center, Columbus, Ohio, United States
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2023-11-01
- Target Recruit Count
- 58
- Registration Number
- NCT03673826
- Locations
- 🇮🇹
IT-Roma-SAPIENZA, Roma, Italy
🇳🇱NL-Hoofddorp-SPAARNEGASTHUIS, Hoofddorp, Netherlands
🇨🇿CZ-Brno-UHBRNO, Brno, Czechia
Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 45
- Registration Number
- NCT03669445
- Locations
- 🇫🇷
CHU Bordeaux, Bordeaux, France
🇫🇷CHU de Dijon, Dijon, France
🇫🇷CHRU de Lille, Lille, France
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 381
- Registration Number
- NCT03651128
- Locations
- 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸Local Institution - 122, Los Angeles, California, United States
🇺🇸Local Institution - 131, Atlanta, Georgia, United States
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 395
- Registration Number
- NCT03652064
- Locations
- 🇺🇸
Cancer And Hematology Centers of Western Michigan PC, Grand Rapids, Michigan, United States
🇺🇸Saint Lukes Hospital Saint Lukes Cancer Specialists, Kansas City, Missouri, United States
🇨🇦Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 560
- Registration Number
- NCT03647124
- Locations
- 🇬🇷
Local Institution - 511, Rio, Patras, Greece
🇬🇷Theageneio General Hospital, Thessaloniki, Thessaloniki, Greece
🇬🇷Metaxa Cancer Hospital, Athens, Piraeous, Greece
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT03641456
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03631043
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.